Top entities: Silo Pharma, Canada — Canadian Intellectual Property Office, United States — Food and Drug Administration, Eric Weisblum, QwikAgents.

What category does this event fall under?

Regulatory — classified as patent allowance.

What is the sentiment of coverage?

Aggregate sentiment score: 10 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated Aug 18, 2026. Coverage continues to evolve.

Regulatory patent allowance

Silo Pharma Canadian Patent Allowance

Q: When did this event occur?

First reported Aug 18, 2026; last updated Aug 18, 2026.

Q: What is the market impact?

General. The patent allowance strengthens Silo Pharma's intellectual property position for SPC-15, potentially enhancing its valuation and competitive standing in the PTSD treatment market.

Analysis based on 7 articles · First reported Aug 18, 2026 · Last updated Aug 18, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The patent allowance strengthens Silo Pharma's intellectual property position for SPC-15, potentially enhancing its valuation and competitive standing in the PTSD treatment market. However, as a developmental-stage company, the immediate financial impact is limited, with the news likely to have a modest positive effect on investor sentiment.

Biopharmaceuticals

Event Summary

Silo Pharma announced that the Canada — Canadian Intellectual Property Office (CIPO) issued a Notice of Allowance for a patent application covering SPC-15, its lead intranasal 5-HT4 receptor agonist for PTSD and other stress-induced psychiatric disorders. The allowed patent, titled 'Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,' covers methods of preventing or delaying stress-induced fear and depressive-like behavior. Silo holds an exclusive license from Columbia University for this patent, part of a broader agreement to develop and commercialize SPC-15 globally. This follows a recently granted European patent for the same invention. Silo plans to use the FDA's 505(b)(2) regulatory pathway, potentially shortening clinical timelines and reducing costs. The company also highlighted its AI subsidiary, QwikAgents.

Key Actions

90 Canada — Canadian Intellectual Property Office issued notice of allowance Silo Pharma

70 Silo Pharma announced patent allowance

Entities Involved

stock

Silo Pharma

Silo Pharma received the Canadian patent allowance for its lead asset SPC-15, strengthening its IP portfolio and supporting its development plans. This is a positive regulatory milestone for the company.

Importance 100.0 Sentiment 20.0

govactor

Canada — Canadian Intellectual Property Office

The Canada — Canadian Intellectual Property Office issued the Notice of Allowance, granting patent protection for SPC-15 in Canada. This is a routine regulatory action.

Importance 80.0 Sentiment 0.0

govactor

United States — Food and Drug Administration

The FDA's 505(b)(2) regulatory pathway is planned for SPC-15 development, which could expedite approval. The FDA's role is regulatory oversight, not directly impacted by this event.

Importance 50.0 Sentiment 0.0

per

Eric Weisblum

Eric Weisblum, CEO of Silo Pharma, commented on the patent allowance, highlighting the company's momentum in securing international IP protection. His leadership is central to the company's strategy.

Importance 40.0 Sentiment 10.0

priv

QwikAgents

QwikAgents, Silo Pharma's AI subsidiary, is mentioned as part of the company's broader strategy but is not directly involved in the patent allowance.

Importance 20.0 Sentiment 0.0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard